V 350B
Alternative Names: V-350BLatest Information Update: 05 Dec 2024
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Epstein-Barr virus infections
Most Recent Events
- 03 Dec 2024 Phase-I clinical trials in Epstein-Barr virus infections (Prevention) in USA (IM) (NCT06655324)
- 23 Oct 2024 Merck Sharp & Dohme plans a phase I trial for Epstein-Barr virus infections (Prevention) (IM, Injection) in November 2024 (NCT06655324)
- 23 Oct 2024 Preclinical trials in Epstein-Barr virus infections (Prevention) in United Kingdom (IM) before October 2024